I just re-listened to part of the shareholder call. Something that stood out to me previously, but I didn't understand what he was saying was Dr. Patterson saying:

in the past we've been looking at ccr5 expression with antibody bodies made by Dickinson an other companies the problem is that doesn't bind to the exact site that Pro 140 does so what we did in our deal is we made sure that when we're doing Diagnostics to see if there's a candidate for pro 140 we're going to use the actual drug as a diagnostic it's elegant it's extremely elegant and it's going to be much more specific and accurate in defining the patients that are going to respond and at the end of the day we're all going to benefit from that so I can't tell you how excited I am about this

Correct me if I am wrong, but are they using this diagnostic tool to test other drugs to see which will best respond when combined with leronlimab and improve outcomes for patients? This will tell us which drugs will benefit most when combining for treatment and would be extremely helpful in partner/license discussions and also which indications to pursue. i.e. I'm sure they chose Regorafenib as it responded best in Dr. Patterson's test?